Pantoprazol Krka (Pantoprazole)

Pantoprazol Krka is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders:

• Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Peptic ulcer disease: supports ulcer healing and reduces the risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare neuroendocrine tumor.
• NSAID‑induced ulcer prophylaxis: lowers the risk of ulcer formation in patients requiring long‑term non‑steroidal anti‑inflammatory therapy.

• Pantoprazole selectively and irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly reduces both basal and stimulated gastric acidity, allowing the mucosa to heal and decreasing acid‑related symptoms.

Pantoprazol Krka is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually transient.
• Nausea: occasional and self‑limiting.
• Abdominal pain: mild discomfort.
• Flatulence: increased gas.
• Constipation: occasional.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Clostridioides difficile infection: persistent watery diarrhea.
• Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.
• Liver enzyme elevation: signs of hepatic dysfunction.
• Bone fractures: increased risk with long‑term use.
• Acute interstitial nephritis: kidney inflammation.

When prescribing Pantoprazol Krka, clinicians should consider several safety aspects:

• Renal impairment: dose adjustment may be required in severe kidney disease.
• Hepatic impairment: monitor liver function in patients with existing liver disease.
• Long‑term therapy: assess need for continued use to minimise fracture risk.
• Drug interactions: review concomitant medications that may affect acid levels or metabolism.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation.
• Store at ambient temperature: keep below 25 °C, protect from moisture and retain in original packaging.

Pantoprazol Krka can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Antifungal agents (e.g., ketoconazole, itraconazole): reduced absorption due to increased gastric pH.
• HIV protease inhibitors (e.g., atazanavir, nelfinavir): markedly decreased plasma concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, requiring closer coagulation monitoring.
• Methotrexate (high‑dose): reduced renal clearance may raise toxicity risk.
• Digoxin: slight increase in serum levels, monitor for toxicity.
• Clopidogrel: possible reduction in antiplatelet effect, consider alternative therapy.